5 Supplements with STRONG Evidence of Benefit

Stanfield builds a comprehensive case for fiber, starting with the 2023 meta-analysis showing a 23% reduction in all-cause mortality. He then details the mechanisms: fiber reduces chronic inflammation, lowers heart disease risk (9% per 7g/day), reduces blood pressure (2.85 points, more in longer trials), blocks cholesterol absorption, increases satiety (14g/day extra led to 10% calorie reduction and 1.9 kg weight loss over 3.8 months), improves blood sugar and insulin sensitivity (34% lower type 2 diabetes risk), feeds gut bacteria to produce short-chain fatty acids that strengthen the gut barrier and reduce systemic inflammation, and is inversely associated with colorectal cancer. He acknowledges that even with a good diet, hitting 25-32g is challenging, so he supplements with psyllium husk. However, he cautions that fiber is not universally beneficial: conditions like Crohn's and certain IBS subtypes may require restriction, and psyllium's effect on IBS is variable—helpful for some, harmful for others.

Stanfield cites a large study where daily multivitamin/mineral use for 2 years improved cognition scores and memory, equivalent to reducing brain aging by about 2 years. He argues that even a good diet may fall short because mineral levels in fruits and vegetables have declined. He then spotlights key ingredients: magnesium (60% of adults don't meet RDA, 45% deficient), vitamin D (guidelines now recommend 800 IU, higher doses harmful), vitamin K2 (bone and potential heart benefits), and B vitamins (brain shrinkage reduction when combined with omega-3). The multivitamin serves as a convenient delivery system for these evidence-backed nutrients.

Stanfield explains magnesium's broad roles—protein synthesis, muscle/nerve function, blood glucose control, blood pressure regulation, bone development, DNA synthesis, and glutathione production. Despite its importance, deficiency is rampant. He notes that fiber-rich foods are also magnesium-rich, so a low-fiber diet often means low magnesium. He prefers magnesium torate because it delivers both magnesium and taurine, which has its own metabolic benefits. This choice reflects his strategy of combining nutrients with overlapping or complementary effects.

Stanfield traces the vitamin D story: after 2011 guidelines, testing and supplementation surged, but RCTs failed to confirm many hoped-for benefits. The Endocrine Society's 2023 revision now recommends 800 IU. He highlights the Canadian trial where 4000 IU and 10000 IU groups lost wrist bone density (2.4% and 3.5%, respectively), while the 400 IU group did not. This paradoxical harm underscores that vitamin D has a U-shaped curve—deficiency is bad, but excess can be detrimental. He uses this to justify a modest intake.

Stanfield first presents the bone health evidence: a 2013 study using 180 mcg MK7 improved bone strength in the lower back and hips, leading to an EFSA-approved health claim. He then discusses the heart health hypothesis—K2 activates matrix Gla protein, which inhibits vascular calcification. Observational data linked higher K2 intake to lower mortality and heart disease. The recent RCT showed a non-significant trend toward less CAC progression overall, but a significant benefit in those with baseline CAC ≥400. He interprets this as promising but preliminary, and personally uses 90 mcg—a lower dose—while awaiting more definitive trials.

Stanfield explains the VITACOG trial (2010) where B vitamins reduced brain atrophy by 29.6%. The 2015 reanalysis revealed that this effect was entirely driven by participants with high plasma omega-3 levels—in them, atrophy reduction was 40%; in low omega-3 individuals, B vitamins did nothing. Another study replicated the pattern. The proposed mechanism: B vitamins lower homocysteine and may facilitate the synthesis of phosphatidylcholine, a phospholipid that shuttles omega-3 into the brain. Thus, both nutrients are required; taking one without the other is likely futile. This insight resolves the inconsistent results of earlier trials and forms the basis for his combined supplementation.

Stanfield reviews the heart benefits: the VITAL trial (840 mg/day) showed a 28% lower heart attack risk and no increased AF; a Mayo Clinic meta-analysis found 13% reduction in heart attacks and 35% reduction in fatal heart attacks. However, the STRENGTH trial (4 g/day) showed a 69% increased AF risk, and a 2024 observational study found 13% higher AF in users. He concludes that the risk is dose-dependent and personally uses ~1 g to capture the benefits while staying below the danger zone. For brain health, he reiterates the synergy with B vitamins, making omega-3 a cornerstone of his cognitive protocol.

Stanfield shifts focus from creatine's well-known muscle benefits to its brain effects. He explains that the brain has high energy demands and creatine helps regenerate ATP quickly, acting as a 'backup battery.' A 2022 meta-analysis found creatine improved memory, with stronger effects in older adults. A 2023 meta-analysis of 16 trials confirmed memory benefits and also showed improvements in attention and processing speed, with a subgroup analysis revealing particular benefits for females. He shares that this evidence convinced his grandmother to start taking creatine, challenging the perception that it's only for male athletes.

Stanfield presents TMG as a multi-benefit supplement. A 2021 study in professional soccer players over 14 weeks showed improvements in 1RM, VO2max, sprinting, and increased testosterone. A 2024 meta-analysis confirmed strength and jumping performance gains. Beyond exercise, he highlights TMG's role as a methyl donor that lowers homocysteine—a 2020 review identified high homocysteine as a strong risk factor for Alzheimer's. Thus, TMG may reduce dementia risk. He notes that TMG, like creatine, supports ATP recycling, and together with a multivitamin, omega-3, and creatine, may synergistically improve brain performance.

Stanfield notes that many over-the-counter melatonin supplements contain very high doses (up to 10 mg), yet long-term safety data are lacking. He calculates that the body naturally produces 10-80 mcg per night, and with ~15% oral absorption, a 300 mcg supplement yields ~45 mcg—within the physiological range. Meta-analyses confirm melatonin reduces sleep onset latency and improves sleep quality. He stresses the importance of taking it 2 hours before desired sleep to shift the circadian rhythm, not just as a sedative. This low-dose, timed approach aims to harness melatonin's chronobiotic effect without unknown risks.

Brad Stanfield opens with this 2023 meta-analysis to anchor the entire fiber discussion. He then walks through the downstream benefits that explain the mortality reduction: fiber combats chronic inflammation (linked to heart disease, Alzheimer's, aging), lowers heart disease risk by 9% per 7g/day increase, reduces blood pressure by ~2.85 points (over 3 points in longer trials), cuts LDL cholesterol by blocking gut absorption, promotes weight loss by increasing satiety (extra 14g/day led to 10% calorie drop and 1.9 kg loss over 3.8 months), improves blood sugar regulation and insulin sensitivity (34% lower type 2 diabetes risk in highest vs lowest consumers), feeds gut bacteria to produce short-chain fatty acids that strengthen the gut barrier and reduce systemic inflammation, and is inversely associated with colorectal cancer. He emphasizes that these effects are not from a single mechanism but a cascade of interconnected benefits, making fiber a uniquely powerful dietary component.

Stanfield explains that the 2011 Endocrine Society guidelines triggered widespread testing and supplementation, but accumulating randomized controlled trials did not support the strong claims. The revised guidelines now recommend 800 IU as sufficient for most people. He underscores the danger of high doses by citing a three-year Canadian trial: participants taking 4,000 IU lost 2.4% wrist bone density, and those on 10,000 IU lost 3.5%, while the 400 IU group did not. This counterintuitive harm—more vitamin D worsening bone health—serves as a caution that 'enough, but not too much' is critical. He uses this to justify his own modest intake via a multivitamin.

Stanfield details the study design: participants were split into placebo and vitamin K2+vitamin D groups, with coronary artery calcium (CAC) scores measured at baseline and after 2 years. Overall, the placebo group accumulated 254 units of calcium vs 203 in the K2 group—a trend that did not reach statistical significance. However, in the subgroup with baseline CAC scores ≥400, the difference was significant. He calls this 'tantalizing evidence' that K2 might prevent vascular calcification, but stresses that the evidence is preliminary and multiple ongoing trials are needed. He personally takes 90 mcg of MK7 while awaiting more data.

Stanfield recounts the VITACOG trial (2010) where B vitamins reduced brain shrinkage by 29.6% over 2 years. The 2015 reanalysis stratified by omega-3 status: in those with high omega-3, the reduction jumped to 40%; in those with low omega-3, B vitamins had zero effect. Another study confirmed the pattern. He then explains the hypothesized mechanism: B vitamins help produce phosphatidylcholine, which is needed to transport omega-3 into the brain. Once inside, omega-3 can exert its anti-inflammatory and structural benefits. This interdependence means that taking either alone may be futile; both must be present. He uses this to justify his combined intake of a B-complex (via multivitamin) and omega-3.

Stanfield presents the 2024 observational data (13% higher AF risk in users), then contrasts two landmark trials: STRENGTH used 4 g/day and found a 69% increased risk of atrial fibrillation; VITAL used 840 mg/day and saw no increased risk. He interprets this as a clear dose-response relationship. To balance the heart attack reduction benefits (28% in VITAL, 13-35% in meta-analyses) with AF risk, he personally settled on ~1 g/day. He warns that many people take high doses unknowingly and may be causing harm.